Skip to content

Vaxcyte, Inc. PCVX Short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84)

Short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84) at other companies

MetLife logo
MetLifeMET
$4.95B-10.7%
Moody's logo
Moody'sMCO
$41M-33.9%
American Electric Power logo
American Electric PowerAEP
$210M
Southern Copper logo
Southern CopperSCCO
$434.1M+98.9%
Equinix, Inc. logo
Equinix, Inc.EQIX
$1.69B+134%
CSX logo
CSXCSX
$145M+1,713%

Other financials

Income statement

See full
Operating income-$345.9M-91.3%
Net income-$320.6M-128%
EPS (diluted)-$2.30-121%

Balance sheet

See full
Cash & equivalents$262.3M-24.7%
Total debt$116.3M+33.5%
Total equity$3.0B-6.4%
Total assets$3.3B-0.9%

Cash flow

See full
Operating cash flow-$280.6M-68.8%
CapEx$2.1M-61.2%
Free cash flow-$282.7M-64.7%

Valuation

See full
Market cap$7.43B+72.0%
Enterprise value$7.28B+78.6%

Returns & leverage

See full
Return on equity-30.6%+37.9pp
Debt / equity0.0×
Current ratio7.5×-10.2×

Where this comes from

Reported directly by Vaxcyte, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ShortTermInvestments.

The official record: Vaxcyte, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Vaxcyte, Inc.'s short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Vaxcyte, Inc.'s short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84)?
Vaxcyte, Inc. (PCVX) reported short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84) of $1.48B in Q1 2026.
How has Vaxcyte, Inc.'s short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84) changed year-over-year?
Vaxcyte, Inc.'s short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84) increased by 11.4% year-over-year, from $1.32B to $1.48B.
What is the long-term trend for Vaxcyte, Inc.'s short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84)?
Over 4 years (2021 to 2025), Vaxcyte, Inc.'s short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84) has grown at a 67.3% compound annual growth rate (CAGR), from $176.99M to $1.39B.
What does short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84) mean?
This represents financial instruments held by the company with maturities greater than one year that are intended to be held for investment purposes rather than immediate liquidity. These assets are often managed to generate returns on excess cash while maintaining a degree of flexibility for future capital needs. It may include restricted assets associated with specific consolidated entities.